Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.
Immune checkpoint
Immunotherapy
Lymphocyte activation gene-3
Molecular imaging
Nanobody
Single-domain antibody
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
02 Nov 2021
02 Nov 2021
Historique:
received:
11
08
2021
accepted:
22
10
2021
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Recent advancements in the field of immune-oncology have led to a significant increase in life expectancy of patients with diverse forms of cancer, such as hematologic malignancies, melanoma and lung cancer. Unfortunately, these encouraging results are not observed in the majority of patients, who remain unresponsive and/or encounter adverse events. Currently, researchers are collecting more insight into the cellular and molecular mechanisms that underlie these variable responses. As an example, the human lymphocyte activation gene-3 (huLAG-3), an inhibitory immune checkpoint receptor, is increasingly studied as a therapeutic target in immune-oncology. Noninvasive molecular imaging of the immune checkpoint programmed death protein-1 (PD-1) or its ligand PD-L1 has shown its value as a strategy to guide and monitor PD-1/PD-L1-targeted immune checkpoint therapy. Yet, radiotracers that allow dynamic, whole body imaging of huLAG-3 expression are not yet described. We here developed single-domain antibodies (sdAbs) that bind huLAG-3 and showed that these sdAbs can image huLAG-3 in tumors, therefore representing promising tools for further development into clinically applicable radiotracers.
Identifiants
pubmed: 34727262
doi: 10.1186/s13550-021-00857-9
pii: 10.1186/s13550-021-00857-9
pmc: PMC8563901
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115Subventions
Organisme : FWO
ID : 1S24218N
Organisme : FWO
ID : 1S05022N
Organisme : FWO
ID : 1S06622N
Organisme : FWO
ID : 1142819N
Organisme : FWO
ID : 1801619N
Organisme : FWO
ID : 1501019N
Informations de copyright
© 2021. The Author(s).
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Brief Bioinform. 2021 May 20;22(3):
pubmed: 32814346
Circ Res. 2012 Mar 30;110(7):927-37
pubmed: 22461363
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Eur Radiol. 2019 Aug;29(8):4294-4302
pubmed: 30506221
J Nucl Med. 2015 Aug;56(8):1265-71
pubmed: 26069306
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
J Nucl Med. 2013 May;54(5):776-84
pubmed: 23487015
Front Immunol. 2021 Mar 09;12:632687
pubmed: 33767701
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Int Immunopharmacol. 2020 Jan;78:106113
pubmed: 31841754
Methods Mol Biol. 2012;911:485-90
pubmed: 22886271
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Oncoimmunology. 2021 Apr 21;10(1):1912892
pubmed: 33996265
Nat Commun. 2018 Nov 7;9(1):4664
pubmed: 30405135
Vaccines (Basel). 2019 Aug 07;7(3):
pubmed: 31394834
J Nucl Med. 2021 Nov;62(11):1638-1644
pubmed: 33712537
N Engl J Med. 2015 Jul 16;373(3):288-90
pubmed: 26176400
Int J Mol Sci. 2021 May 17;22(10):
pubmed: 34067904
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Bioorg Med Chem. 2020 Sep 1;28(17):115634
pubmed: 32773089
Biomolecules. 2020 Sep 29;10(10):
pubmed: 33003481
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Clin Oncol. 2017 Dec 1;35(34):3867-3876
pubmed: 29053400
Biomolecules. 2021 Apr 26;11(5):
pubmed: 33925941
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Cancers (Basel). 2020 Oct 29;12(11):
pubmed: 33137949
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234464
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374804
Bioconjug Chem. 2014 May 21;25(5):979-88
pubmed: 24815083
Nat Med. 2018 Dec;24(12):1852-1858
pubmed: 30478423
Leukemia. 2014 Feb;28(2):444-7
pubmed: 24166214
Contrast Media Mol Imaging. 2016 Sep;11(5):328-339
pubmed: 27147480
Biomolecules. 2019 Sep 29;9(10):
pubmed: 31569553
Int Immunopharmacol. 2018 Sep;62:29-39
pubmed: 29990692
J Nucl Med. 2018 Jun;59(6):885-891
pubmed: 29545374
Pharmaceuticals (Basel). 2021 Jun 08;14(6):
pubmed: 34201323
Theranostics. 2017 Jul 14;7(11):2924-2939
pubmed: 28824726
Mol Imaging Biol. 2019 Oct;21(5):898-906
pubmed: 30671739
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
Hum Gene Ther. 2007 Jun;18(6):536-46
pubmed: 17576158
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):528-533
pubmed: 26630549
J Nucl Med. 2016 Jan;57(1):27-33
pubmed: 26449837
J Hematol Oncol. 2018 Dec 21;11(1):142
pubmed: 30577797